## Julie Teruya-Feldstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7197166/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitiory pathway. Science, 2019, 364, .	12.6	194
2	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell, 2018, 33, 29-43.e7.	16.8	186
3	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. Journal of Clinical Investigation, 2020, 130, 733-747.	8.2	161
4	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	11.1	114
5	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 2021, 27, 2099-2103.	30.7	92
6	LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. HemaSphere, 2018, 2, e54.	2.7	74
7	Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis. Cell Reports, 2019, 28, 2480-2490.e4.	6.4	66
8	Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. Cell Stem Cell, 2017, 21, 489-501.e7.	11.1	58
9	Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression. Cancer Research, 2016, 76, 664-674.	0.9	47
10	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	4.8	43
11	#InSituPathologists: how the #USCAP2015 meeting went viral on Twitter and founded the social media movement for the United States and Canadian Academy of Pathology. Modern Pathology, 2017, 30, 160-168.	5.5	39
12	Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood, 2015, 126, 2479-2483.	1.4	36
13	Integrative RNA-omics Discovers <i>GNAS</i> Alternative Splicing as a Phenotypic Driver of Splicing Factor–Mutant Neoplasms. Cancer Discovery, 2022, 12, 836-855.	9.4	19
14	Atypical lymphocyte morphology in SARS-CoV-2 infection. Pathology Research and Practice, 2020, 216, 153063.	2.3	17
15	Hypersegmented granulocytes and COVID-19 infection. Blood, 2020, 135, 2196-2196.	1.4	12
16	<i>NPM1</i> ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by <i>p53</i> loss. EMBO Reports, 2022, 23, e54262.	4.5	12
17	nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 644-648.	1.2	9
18	MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type. Laboratory Investigation, 2019, 99, 539-550.	3.7	9

Julie Teruya-Feldstein

#	Article	IF	CITATIONS
19	Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal. Academic Pathology, 2021, 8, 2374289521990823.	1.1	7
20	EpCam is required for maintaining the integrity of the biliary epithelium. Liver International, 2021, 41, 2132-2138.	3.9	4
21	Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma. Modern Pathology, 2020, 33, 188-195.	5.5	3
22	Burkitt lymphoma of the nasopharynx causing life-threatening airway obstruction: A case report. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 102977.	1.3	3
23	Immune dysregulation: EBV+ DLBCL and HLH in a patient with T-LGL. Blood, 2019, 133, 1695-1695.	1.4	2
24	A Rare Cause of Pancytopenia in an Exclusively Breastfed Infant. Journal of Pediatric Hematology/Oncology, 2019, 41, e322-e324.	0.6	2
25	Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, e63-e64.	1.2	2
26	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e341-e344.	0.4	2
27	Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses. Blood, 2016, 128, 962-962.	1.4	2
28	Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia. Blood, 2015, 126, 2551-2551.	1.4	1
29	Hemophagocytic relapsed intramedullary plasmacytoma. International Journal of Hematology, 2020, 111, 888-890.	1.6	0
30	Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica, 2020, 105, e91-e94.	3.5	0